Value of Medication Adherence in Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be âmobile biomarkers,â meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.